NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia

Prior treatment

• Previous gene therapy treatment;

Other illness

• Positive for hepatitis B surface antigen, hepatitis C, human immunodeficiency virus (HIV) or syphilis test;
• Uncontrolled myocardial infarction or heart failure, or had surgery plan within 1 year;
• Acute or chronic kidney failure;
• Had contraindications to glucocorticoid (e.g., epilepsy, severe schizophrenia, active peptic ulcer);
• With malignant tumors;
• Liver fibrosis or liver cancer;
• Hypersensitivity to any excipient of the AAV product (including trehalose) or cortisone or immunosuppressants (sirolimus, rituximab, tacrolimus);
• History of stent implantation within 1 month or myocardial infarction within 3 months;
• Any other condition that may not be appropriate for the study in the opinion of the Investigator.

Lab values

• Clinically significant abnormalities in liver function test: alanine aminotransferase (ALT) \>3 × upper limit of normal (ULN) and/or aspartate aminotransferase (AST) \>3 × ULN;
• Diabetes diagnosed within 3 months or with poor control (HbA1c \>9%);
• Hemoglobin (Hb) \<120g/L (male), Hb \<110 (female);
• Platelet test results deemed clinically significantly abnormal by the investigator;
• History or laboratory tests suggestive of thrombosis;

Other

• Baseline blood pressure \>160/100 mmHg (1 repeat measurement is allowed);
• Life expectancy less than 1 year;
• Participation in any other clinical trial within 3 months;
• Breastfeeding females;

• Voluntarily sign informed consent form;
• Male or female, 12 ≤ age ≤ 55 years (first patient≥ 18 years), diagnosed as homozygous familial hypercholesterolemia with genetic confirmation of two mutant alleles of the LDL receptor (LDLR) gene;
• AAV8 neutralizing antibodies can be negative or reduced to negative levels through methods such as plasma exchange or IgG-degrading enzymes.
• Untreated LDL-C ≥10 mmol/L (386mg/ dL) or treated LDL-C ≥7 mmol/L (270mg/ dL) together with cutaneous or tendon xanthoma before age 18 years;
• Had been on stable medication for ≥30 days if receiving lipid-lowering therapy (or ≥60 days if receiving alirocumab or evolocumab) prior to screening and not scheduled for addition of new drugs or dose adjustments during the study;
• Agreed to follow a low-fat diet and comply with all study procedures, including dietary requirements, study visits, fasting blood draws, and the study treatment regimen.;
• Agreed to maintain a similar exercise volume and intensity to baseline during the study period;
• Agreed to maintain good lifestyle habits;
• No history of alcohol abuse or alcohol dependence (diagnosed as F10 in ICD-10 code);
• No sexual activity for 14 days prior to administration and negative serum pregnancy test in female participants;
• Participants of childbearing potential agreed to use highly effective contraception for at least 365 days from administration of NGGT006;
• No plan of stent implantation within 3 months.